| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Lenalidomide |
| Brand | Revlimid® |
| Indication | For the treatment of adult patients with previously untreated multiple myelomas (MM) who are not eligible for transplant (licence extension). |
| Assessment Process | |
| Rapid review commissioned | 05/10/2015 |
| Rapid review completed | 20/11/2015 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended at the submitted price |
Approved following confidential price negotiation for lenalidomide across all licensed indications (January 2018).